Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
Abstract In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response